Target Name: CD52
NCBI ID: G1043
Review Report on CD52 Target / Biomarker Content of Review Report on CD52 Target / Biomarker
CD52
Other Name(s): EDDM5 | CDW52 antigen (CAMPATH-1 antigen) | CDw52 | HE5 | epididymal secretory protein E5 | CD52_HUMAN | CDW52 | he5 | CD52 antigen | Epididymal secretory protein E5 | cambridge pathology 1 antigen | Cambridge pathology 1 antigen | Human epididymis-specific protein 5 | epididymis secretory sperm binding protein Li 171mP | HEL-S-171mP | CAMPATH-1 antigen | CD52 molecule | human epididymis-specific protein 5 | Epididymis secretory sperm binding protein Li 171mP | CD52 antigen (CAMPATH-1 antigen) | CAMPATH-1 | He5

CD52: A Potential Drug Target and Biomarker

Introduction

CD52, a cell surface protein located on the surface of immune cells, plays a crucial role in the immune response against infections and diseases. It is a key player in the regulation of T-cell activation and proliferation, making it an attractive drug target for researchers. In this article, we will explore the biology of CD52, its potential as a drug target, and its potential as a biomarker for various diseases.

CD52: Structure and Function

CD52 is a 52kDa protein that is expressed in most tissues of the body, including the skin, hair, and nails. It is a member of the immunoglobulin superfamily and is responsible for regulating the activation and proliferation of T-cells (2 ). CD52 functions as a negative regulator of the T-cell receptor (TCR), which is responsible for recognizing and responding to antigens in the environment.

CD52 plays a crucial role in the regulation of T-cell activation and proliferation. It is involved in the negative regulation of CD28, which is a critical co-stimulator of T-cell activation. CD52 binds to CD28 and inhibits its activity , preventing T-cell activation from happening.

CD52 is also involved in the regulation of T-cell proliferation. It has been shown to play a role in the negative regulation of cell proliferation, by preventing the phosphorylation and activation of the B-cell kinase, which is responsible for cell proliferation (6 ).

Potential Drug Target

CD52 has been identified as a potential drug target due to its involvement in the regulation of T-cell biology. Because it can be used as a drug target to inhibit the activation of CD28 during T cell activation, thereby inhibiting the activation of T cells and reducing immunity. The intensity of the response has potential application value in the treatment of autoimmune diseases, inflammatory diseases, tumors and other diseases.

CD52 has been shown to be a good candidate for a monoclonal antibody (mAb) drug, due to its high expression level, long half-life, and multiple immunogenic sites. Currently, multiple companies have developed drugs targeting CD52 mAbs, these mAbs have good pharmacokinetics and biological activity, bringing hope to CD52 as a drug target.

Biomarker

In addition to being a drug target, CD52 also has potential as a biomarker. In certain diseases, such as autoimmune diseases, inflammatory diseases and tumors, CD52 levels change and can therefore be used as biomarkers for these diseases.

For example, in autoimmune diseases, CD52 levels are increased, while in inflammatory diseases, CD52 levels are decreased. These changes in CD52 levels can be used as biomarkers to monitor disease activity and response to treatment, and to track the effectiveness of different therapies.

Conclusion

CD52 is a protein that plays a critical role in the immune response against infections and diseases. Its role in regulating T-cell activation and proliferation makes it an attractive drug target for researchers. Currently, several companies have developed monoclonal antibodies (mAbs) targeting CD52 , which have the potential to be useful in the treatment of various diseases. Additionally, CD52 levels can be used as biomarkers to monitor disease activity and response to treatment. Further research is needed to fully understand the role of CD52 in the immune response and its potential as a drug target and biomarker.

Protein Name: CD52 Molecule

Functions: May play a role in carrying and orienting carbohydrate, as well as having a more specific role

The "CD52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26